Trial Profile
A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800, or 1600 mg/Day of S-2367 Administered Orally Once Daily With a Reduced Calorie Diet in Obese Males and Females.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Velneperit (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shionogi USA
- 24 Oct 2009 Results presented at the 2009 Annual Meeting of the North American Association for the Study of Obesity (NAASO 2009).
- 24 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2009 Secondary endpoint analysis is ongoing, according to a Shionogi media release.